Anavex Life Sciences Corp (AVXL)

[seventhwave]

I've been tuned out for 3 months now and as we close out another year with very little to show in terms of trial results, I'm left wondering...

Why did the Alzheimer's p2b and other trials have to wait for the completion of biomarker & RWE analysis with Ariana, et. al. if none of its findings were to be applied to screening for patients in these subsequently started trials??? The Alzheimer's p2a part a completed in July 2016.

None of the outcomes of ANY of these trials (that have pending results) will be influenced by these biomarker/RWE studies.

Were the biomarker/RWE analyses to determine whether or not to pull the plug on further trials? All they will do is produce some nice-to-have additional data which Missling might use to do repeat trials on subgroups if the current studies fail.

It's been one massive boondoggle! All my other biotechs have demonstrated progress. The only saving grace is Missling hasn't burnt money like most other CEOs and share price has been more-or-less perserved despite ATM activity.